Pioglitazone Therapy
Research from LG Has Provided New Information about Pioglitazone Therapy
Published in Drug Week, March 23rd, 2012
2012 MAR 23 -- According to the authors of recent research from Seoul, South Korea, "LC15-0444, a newly developed selective dipeptidyl peptidase IV inhibitor, has the potential to be administered with other antihyperglycemic agents. The aim of this study was to investigate the interaction between LC15-0444 and pioglitazone by comparing the pharmacokinetics of both compounds and their metabolites."
"A randomized, open-label, multiple dosing, three-sequence, three-period, three-treatment crossover study was performed in healthy volunteers. The three treatment groups were comprised of LC15-0444 200 mg, pioglitazone 30 mg, or coadministration of both drugs once...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2012-03-23)
More Articles from Drug Week
- Pseudomonas
Yantai Institute of Coastal Zone Research Publishes Research in Pseudomonas - Glioblastomas
Yale University Reports Research in Glioblastomas - Cell Surface Receptors
Yale University Publishes Research in Cell Surface Receptors - Alcohol Oxidoreductases
Wenzhou Medical College Details Research in Alcohol Oxidoreductases - Antibiotics
Xinyang Normal University Details Research in Antibiotics - Weight Loss
Wellspring at Structure House Announces New Executive Director, Thomas Britton - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
